Citigroup’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$65.6M Buy
1,045,000
+750,000
+254% +$60M 0.03% 542
2025
Q4
$28.1M Sell
295,000
-609,900
-67% -$59.8M 0.01% 918
2025
Q3
$88.3M Buy
904,900
+817,600
+937% +$84.7M 0.04% 419
2025
Q2
$9.38M Sell
87,300
-343,700
-80% -$34.8M ﹤0.01% 1418
2025
Q1
$43.5M Sell
431,000
-85,000
-16% -$8.56M 0.02% 598
2024
Q4
$46.1M Sell
516,000
-4,100
-0.8% -$361K 0.03% 554
2024
Q3
$43.6M Buy
520,100
+134,000
+35% +$10.6M 0.03% 592
2024
Q2
$29.7M Buy
386,100
+194,100
+101% +$14.2M 0.02% 714
2024
Q1
$13.2M Sell
192,000
-30,000
-14% -$1.93M 0.01% 1097
2023
Q4
$12.8M Buy
222,000
+140,000
+171% +$7.47M 0.01% 1091
2023
Q3
$4.33M Buy
82,000
+17,000
+26% +$892K ﹤0.01% 1516
2023
Q2
$3.52M Buy
65,000
+35,000
+117% +$1.83M ﹤0.01% 1736
2023
Q1
$1.5M Buy
+30,000
New +$1.41M ﹤0.01% 2217
2022
Q3
Sell
-250,000
Closed -$9.32M 5853
2022
Q2
$9.32M Buy
250,000
+96,800
+63% +$3.94M 0.01% 1190
2022
Q1
$6.79M Sell
153,200
-355,800
-70% -$15.4M ﹤0.01% 1502
2021
Q4
$21.6M Buy
509,000
+249,000
+96% +$10.5M 0.01% 967
2021
Q3
$11.3M Hold
260,000
0.01% 1332
2021
Q2
$11.1M Hold
260,000
0.01% 1349
2021
Q1
$10M Sell
260,000
-34,300
-12% -$1.3M 0.01% 1368
2020
Q4
$10.6M Buy
294,300
+31,900
+12% +$1.15M 0.01% 1506
2020
Q3
$10M Buy
262,400
+104,800
+66% +$4.04M 0.01% 1373
2020
Q2
$5.53M Sell
157,600
-82,200
-34% -$2.96M ﹤0.01% 1772
2020
Q1
$7.83M Sell
239,800
-45,500
-16% -$1.78M 0.01% 1324
2019
Q4
$12.9M Sell
285,300
-17,500
-6% -$732K 0.01% 1269
2019
Q3
$12.3M Buy
302,800
+214,800
+244% +$9.1M 0.01% 1248
2019
Q2
$3.78M Sell
88,000
-61,400
-41% -$2.36M ﹤0.01% 2211
2019
Q1
$5.73M Sell
149,400
-35,400
-19% -$1.35M 0.01% 1672
2018
Q4
$6.53M Sell
184,800
-221,700
-55% -$8.04M 0.01% 1599
2018
Q3
$15.7M Buy
406,500
+168,200
+71% +$5.87M 0.01% 997
2018
Q2
$7.79M Buy
238,300
+109,500
+85% +$3.3M 0.01% 1467
2018
Q1
$3.52M Sell
128,800
-55,400
-30% -$1.51M ﹤0.01% 2092
2017
Q4
$4.57M Buy
184,200
+72,700
+65% +$2.01M ﹤0.01% 1915
2017
Q3
$3.25M Buy
111,500
+48,100
+76% +$1.33M ﹤0.01% 2156
2017
Q2
$1.76M Sell
63,400
-78,000
-55% -$2.07M ﹤0.01% 2723
2017
Q1
$3.52M Buy
141,400
+71,800
+103% +$1.75M ﹤0.01% 1955
2016
Q4
$1.5M Sell
69,600
-14,800
-18% -$323K ﹤0.01% 3258
2016
Q3
$2.01M Buy
84,400
+35,700
+73% +$852K ﹤0.01% 2506
2016
Q2
$1.14M Sell
48,700
-55,100
-53% -$1.19M ﹤0.01% 2830
2016
Q1
$1.95M Buy
103,800
+58,100
+127% +$1.02M ﹤0.01% 2519
2015
Q4
$843K Sell
45,700
-42,000
-48% -$753K ﹤0.01% 3330
2015
Q3
$1.44M Buy
87,700
+9,300
+12% +$159K ﹤0.01% 2745
2015
Q2
$1.39M Sell
78,400
-30,900
-28% -$552K ﹤0.01% 2878
2015
Q1
$1.94M Buy
109,300
+15,700
+17% +$248K ﹤0.01% 2504
2014
Q4
$1.24M Sell
93,600
-25,000
-21% -$320K ﹤0.01% 2920
2014
Q3
$1.4M Buy
118,600
+47,300
+66% +$596K ﹤0.01% 2804
2014
Q2
$911K Sell
71,300
-103,300
-59% -$1.34M ﹤0.01% 3032
2014
Q1
$2.36M Buy
174,600
+49,700
+40% +$652K ﹤0.01% 2243
2013
Q4
$1.5M Sell
124,900
-69,600
-36% -$822K ﹤0.01% 2828
2013
Q3
$2.28M Buy
194,500
+26,500
+16% +$287K ﹤0.01% 2369
2013
Q2
$1.56M Buy
+168,000
New +$1.43M ﹤0.01% 2553

Other funds holding BSX

Citigroup's BSX Position: Q1 2026 in Review

Citigroup increased its Boston Scientific (BSX) stake by 16% in Q1 2026, buying an estimated $17.6M and bringing the position to 1,576,640 shares worth $98.9M. The position accounts for 0.04% of the portfolio, ranked #409.

Citigroup first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $433M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Citigroup held 1,576,640 shares of Boston Scientific worth $98.9M as of Q1 2026.
  • Citigroup bought 220,141 Boston Scientific shares in Q1 2026, an estimated $17.6M.
  • Boston Scientific made up 0.04% of Citigroup's portfolio in Q1 2026, its #409 holding.
  • Citigroup first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Boston Scientific position peaked at $433M in Q2 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.